AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22394471
Drug: Org 25935
RxNorm normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25935 (12 mg)
Trial: 18706998
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered budesonide
Trial: 11039260
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 2,500 mg/day (1,000 mg of calcium)
Trial: 11039260
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate 1,000 mg (254 mg of calcium)
Trial: 6394349
Drug: Piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide 6 mg b.d.
Trial: 6394349
Drug: Piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide 6 mg + Triamterene 50 mg b.d.
Trial: 6394349
Drug: Triamterene 50
RxNorm normalized name: triamterene 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene 50 mg b.d.
Trial: 23506257
Drug: Barrier cream
RxNorm normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier cream (40% zinc oxide with cod liver oil formulation)
Trial: 23776431
Drug: Low-vitamin B-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-vitamin B-6 diet (<0.5 mg/d)
Trial: 18821708
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucosamine and chondroitin sulfate
Trial: 15940172
Drug: Entero-sorption with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entero-sorption with pectin-containing medication
Trial: 12463728
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (two slices of bread and 200 ml of apple juice)
Trial: 12463728
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (two slices of bread with 30 gm of butter and 200 ml of apple juice)
Trial: 10328649
Drug: Regenerative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative therapy using bioactive glass
Trial: 1754868
Drug: IS-5-MN 20
RxNorm normalized name: IS 5-MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IS-5-MN 20 mg b.i.d. or t.i.d.
Trial: 1754868
Drug: s.r. nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.r. nifedipine 20 mg b.i.d. or 40 mg b.i.d.
Trial: 7127996
Drug: Flecainide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (200 to 300 mg b.i.d.)
Trial: 31551206
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg orally once daily for the first 21 days of each 28‐day cycle plus Best Supportive Care (BSC)
Trial: 31551206
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 intravenously on Day 1 of each 21‐day cycle plus cisplatin 75 mg/m2 i.v. beginning 30 minutes after pemetrexed administration plus Best Supportive Care (BSC)
Trial: 29149904
Drug: 7-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day standard triple therapy (lansoprazole, amoxicillin, and clarithromycin)
Trial: 29149904
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days)
Trial: 29149904
Drug: 10-day concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Trial: 26335108
Drug: Interactive videogame
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive videogame therapy (VGT)
Trial: 26335108
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy ROM activities (ST)
Trial: 22947344
Drug: Subcutaneous allergen-specific
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract
Trial: 19237874
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (insulin titrated to maintain blood glucose levels within the range of 4.44‐6.11 mM)
Trial: 17389707
Drug: Hormone-sensitive lipase
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone-sensitive lipase gene expression
Trial: 3816921
Drug: Slow-release diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release diltiazem (120 mg)
Trial: 3816921
Drug: Conventional diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diltiazem tablet (120 mg)
Trial: 30488789
Drug: Rivaroxaban (direct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (direct oral anticoagulant)
Trial: 24397361
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone capsules 200 mg once daily from the day after insemination until next menstruation or continuing for up to 8 weeks of pregnancy.
Trial: 1771216
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexamethasone phosphate
Trial: 1771216
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone phosphate
Trial: 21092353
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted CBT combined with antidepressants
Trial: 21092353
Drug: Antidepressants alone
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants alone (treatment as usual)
Trial: 7988854
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (3.6 mg goserelin depot injection on cycle day 22 followed by individualized HMG stimulation 14 days later)
Trial: 2659475
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with slow-release theophylline (2 x 350 mg) and salbutamol aerosol
Trial: 2659475
Drug: Salbutamol monotherapy
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol monotherapy (placebo capsules)
Trial: 2659475
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with slow-release theophylline and salbutamol aerosol
Trial: 1148964
Drug: Cephaloridine (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephaloridine (prophylactic antibacterial therapy)
Trial: 28524025
Drug: Esmolol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.05 mg×kg‐1×h‐1, titrated to decrease heart rate by 20% or below 95 bpm)
Trial: 28524025
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic saline at 3 mL/h for 24 hours)
Trial: 21948965
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg three times daily for 20 days
Trial: 19838080
Drug: Tdap and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap and TIV co-administered
Trial: 19838080
Drug: Tdap and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap and TIV sequential administration (TIV followed by Tdap)
Trial: 16759390
Drug: Lutein supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein supplementation (10 mg/d for 12 weeks followed by 30 mg/d for 12 weeks)
Trial: 15568661
Drug: Single-dose morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose morning omeprazole
Trial: 15568661
Drug: Single-dose morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose morning rabeprazole
Trial: 15568661
Drug: Single-dose morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose morning famotidine
Trial: 15568661
Drug: Single-dose evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose evening omeprazole
Trial: 15568661
Drug: Single-dose evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose evening rabeprazole
Trial: 9489411
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of chronic pulmonary tuberculosis with 4-6 antituberculous drugs for not less than one year after sputum culture conversion.
Trial: 9489411
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with 3 or 4 drugs for recently diagnosed pulmonary tuberculosis.
Trial: 8454118
Drug: Discussion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussion of treatment effects
Trial: 29183926
Drug: Enhanced management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced management with 3 monthly follow-up
Trial: 29183926
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual by the general practitioner
Trial: 25752882
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg DEX
Trial: 25752882
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg DEX
Trial: 25752882
Drug: Prophylactic DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic DEX (4 mg) vs. steroid naïve cohort
Trial: 17004982
Drug: Intravenous ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferrous sucrose 200 mg (two doses on days 2 and 4)
Trial: 17004982
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate 200 mg twice daily for 6 weeks
Trial: 17004982
Drug: Intravenous ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferrous sucrose
Trial: 14762881
Drug: Irradiation (60-66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation (60-66 Gy over 30-33 daily fractions)
Trial: 9205634
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg effervescent calcium tablet, Sandocal 1000)
Trial: 7960357
Drug: 1% 8-MOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% 8-MOP bathing suit treatment
Trial: 7960357
Drug: Placebo bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bathing suit treatment
Trial: 29437941
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (40 mg.kg(‐1))
Trial: 27686002
Drug: Low-dose azathioprine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose azathioprine in combination with allopurinol
Trial: 25070123
Drug: Thermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal therapy using an infrared thermal blanket at 50°C for 40 minutes in addition to drug treatment
Trial: 18485668
Drug: Grape antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape antioxidant dietary fiber (7.5 g/d)
Trial: 18485668
Drug: Grape antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape antioxidant dietary fiber (7.5 g/d) in hypercholesterolemic subjects
Trial: 11476456
Drug: Fexofenadine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 15 mg twice daily
Trial: 11476456
Drug: Fexofenadine 30
RxNorm normalized name: fexofenadine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 30 mg twice daily
Trial: 9595871
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg taken 5 hours before the endogenous nocturnal plasma melatonin concentration reached 10 pg/mL
Trial: 7802194
Drug: Hyaluronidase 50
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase 50 u.ml‐1 added to local anaesthetic mixture
Trial: 15235828
Drug: Intravenous famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous famotidine (20 mg administered one hour before surgery)
Trial: 15235828
Drug: Intramuscular famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular famotidine (20 mg administered one hour before surgery)
Trial: 15235828
Drug: Oral famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral famotidine (20 mg administered the night before and on the morning of surgery)
Trial: 21332976
Drug: AMC/DCBA Warm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMC/DCBA Warm lozenge
Trial: 21332976
Drug: AMC/DCBA Cool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMC/DCBA Cool lozenge
Trial: 21332976
Drug: Unflavoured, non‐medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unflavoured, non‐medicated lozenge
Trial: 21683485
Drug: Specially formulated
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specially formulated medical food (40 g protein, enriched with 10% free leucine)
Trial: 21683485
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical food (24 g casein protein)
Trial: 19921981
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice 50 ml daily (n=28)
Trial: 19921981
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG drink 100 ml on 5 days a month (n=27)
Trial: 15855510
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous infusion over 30 min t.i.d.
Trial: 15855510
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg loading dose followed by 1,500 mg continuous infusion over 24 h
Trial: 15855510
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg intravenous infusion over 30 min t.i.d.
Trial: 15855510
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg loading dose followed by 3,000 mg continuous infusion over 24 h
Trial: 15855510
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion
Trial: 15855510
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy as continuous infusion
Trial: 12791417
Drug: NN2211 (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN2211 (GLP-1 derivative), dose levels: eight, administered before glucose dose
Trial: 7875920
Drug: Waking analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waking analgesia followed by hypnotic analgesia
Trial: 7875920
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia followed by waking analgesia
Trial: 30687908
Drug: Non-ablative vaginal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ablative vaginal erbium:YAG laser (VEL) treatment (20 min/session, thrice)
Trial: 30687908
Drug: Anticholinergic agent
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic agent (4 mg fesoterodine)
Trial: 30687908
Drug: β3-adrenoceptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β3-adrenoceptor agonist (25 mg mirabegron)
Trial: 29055680
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU intranasal OXT
Trial: 26567120
Drug: Antihypotensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypotensive therapy
Trial: 26567120
Drug: No antihypotensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypotensive therapy
Trial: 19149837
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy (HRT) - continuous 17-beta estradiol patch at 36 microg/day plus cyclic oral medroxyprogesterone acetate 2.5 mg/day for 12 days/month
Trial: 17017752
Drug: Ayurvedic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ayurvedic intervention (exercise, Ayurvedic diet, meditation instruction, Ayurvedic herb supplement MA 471)
Trial: 12834197
Drug: CC atrophy
RxNorm normalized name: Jatropha curcas seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC atrophy in CDR 1 & 2 patients
Trial: 12834197
Drug: Frontal executive
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal executive dysfunction associated with CC atrophy
Trial: 12834197
Drug: CC atrophy
RxNorm normalized name: Jatropha curcas seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC atrophy and WMH correlation
Trial: 12834197
Drug: Combined effect
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined effect of CC atrophy and WMH in verbal fluency test
Trial: 9315426
Drug: Various HIV-related
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various HIV-related medications
Trial: 1535110
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for myocardial infarction (exact treatments not specified)
Trial: 1535110
Drug: Treatments with
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments with no effect on mortality or potentially harmful treatments (control group)
Trial: 4077377
Drug: Collagen protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen protein (1.3 g/kg desirable body weight per day)
Trial: 4077377
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (1.3 g/kg desirable body weight per day)
Trial: 29931143
Drug: Oxandrolone (Ox)
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone (Ox) 0.05 mg/kg for 2 years
Trial: 23279918
Drug: Brief Motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Motivational Interviewing (BMI) in conjunction with Traditional Oral Health Education (TOHE) (n = 29)
Trial: 23279918
Drug: Traditional Oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Oral Health Education (TOHE) alone (n = 27)
Trial: 16749288
Drug: Coronary reperfusion
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary reperfusion therapy
Trial: 11714046
Drug: Piperacillin/Tazobactam (100/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam (100/12.5 mg/kg every 8 h)
Trial: 11714046
Drug: Cefotaxime plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime plus Metronidazole (50/7.5 mg/kg every 8 h)
Trial: 7533224
Drug: Moxonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.2 mg b.i.d.)
Trial: 3216030
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral tablet of dilevalol
Trial: 3216030
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous infusion of dilevalol
Trial: 29193419
Drug: Artichoke leaf
RxNorm normalized name: artichoke leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke leaf extract (ALE) supplementation (1,800 mg hydroalcoholic extract as four tablets per day)
Trial: 29193419
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn starch, lactose, and avicel as four tablets per day)
Trial: 24193155
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 8 weeks (q8w)